Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

We're covering the myriad ways GLP-1 weight loss drugs are changing people's lives. (Photo illustration: Yahoo News; photos: ...

How tirzepatide works for weight loss Tirzepatide is a type of medication known as a GLP-1 agonist, which means it mimics a naturally-occurring hormone in the body called a peptide to influence a ...

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.“Despite being the ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Overall, the study found that tirzepatide was more effective at helping participants lose weight. About 82% of participants taking tirzepatide experienced 5% or greater weight loss.

Diabetes drug Tirzepatide, which is shown to be more effective than Wegovy and Ozempic, is likely to be approved by the Food and Drug Administration for weight loss in 2023 and is expected to be ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...